What is AZN's current stock price?

As of now, AZN is trading at $91.11, with a daily change of +1.04%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

AZN Stock Analysis & IQ Rating | Astrazeneca

AZN

Astrazeneca

$91.11

+$0.94 | +1.04%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$94.02

MKT CAP

$285.62B

52W Low

$61.24

VOL

$1.66M

P/E Ratio

30.27

AVG VOL

$4.91M

RSI

61.32

TREND

Uptrend

AZN Stock IQ

Login to see Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

AZN Target Price

Login to display

Strengths

AZN Rewards

Earnings are forecast to grow

AZN Rewards

Upgraded on attractively valued

AZN Rewards

Trading below its fair value

AZN Rewards

Outperform the market

AZN Price Performance

$81.35 (+12.00%)

$81.22 (+12.18%)

$71.85 (+26.81%)

$66.23 (+37.57%)

1year

6month

3month

1month

AZN Risk Level

AZN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

AZN Analysts Opinion

AZN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

AZN Analysts Opinion

AZN Analysts opinion is negative and it remained unchanged from the past 3 months

AZN Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

96%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

75%

AZN Street Sentiment

AZN Street Sentiment is extremely bullish and have positive views on the near-term outlook

AZN Performance Sentiment

Sentiments overview associated with AZN events and the stock performance.

96%

0%

Positive

Negative

22 out of 23
events present

0 out of 23
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$93.32

Resistance
Price

$73.53

Current Price Range

$93.32

Show methods +

Linked to AZN

IQ

Close Price

Change

NVS

4.27

133.87

+1.17%

PFE

3.94

25.57

+1.65%

MRK

4.03

102.08

+1.05%

SNY

4.02

49.85

+0.02%

TEVA

4.23

27.29

+1.54%

AZN Latest Analysis +

AstraZeneca (AZN) Named One of BofAs Top 25 Stocks for 2026. AstraZeneca PLC (NASDAQ:AZN) ranks among the Best Low Volatility Investments in December 2025. BofA Securities maintained its Buy rating on AstraZeneca PLC (NASDAQ:AZN) and increased its price target to $108.50 from $91.70 on November 25. AstraZeneca PLC (NASDAQ:AZN) was listed on the companys Europe 1 list of top ideas and ranked as one of its [….]

Today

$91.11 | +1.04%

Rating

AstraZeneca Hypertension Drug Baxdrostat Wins FDA Priority Review . (RTTNews) - AstraZenecas (AZN) New Drug Application (NDA) for experimental hypertension drug baxdrostat has been granted Priority Review by the United States Food and Drug Administration.

Tue Dec 2, 2025

$90.17 | -0.39%

Activity

Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight. Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies |. DelveInsightThe dynamics of the geographic atrophy market are expected to change in the coming years due to the rising global prevalence driven by aging populations demand for disease-mod

Mon Dec 1, 2025

$90.52 | -2.38%

Activity

Peter Lynch Detailed Fundamental Analysis - AZN. Below is Valideas guru fundamental report for ASTRAZENECA PLC (ADR) (AZN). Of the 22 guru strategies we follow AZN rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price rel

Mon Dec 1, 2025

$90.52 | -2.38%

Potential

United States Pushes United Kingdom to Spend More on Medicines in Deal to Avoid Tariffs. A lab run by the drugmaker AstraZeneca. President Trump has complained that wealthy European countries pay too little for medicines.

Mon Dec 1, 2025

$90.52 | -2.38%

Activity

Heres Why Astrazeneca (AZN) is a Strong Growth Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Fri Nov 28, 2025

$92.73 | -0.63%

Potential

AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers. The United States Food and Drug Administration (FDA) on Tuesday approved ) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil leucovorin oxaliplatin and docetaxel) for resectable early-stage and locally advanced gastric and .AZN is in positive territory. The approved regimen includes neoadjuvant(therapy before surgery) Imfinzi in combination with chemotherapy before

Wed Nov 26, 2025

$93.32 | +0.09%

Activity

AstraZeneca Announces Approval Of Imfinzi In The US . (RTTNews) - AstraZeneca (AZN AZN.L) said its Imfinzi or durvalumab in combination with standard-of-care FLOT chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage and locally advanced gastric and gastroesophageal junction can

Wed Nov 26, 2025

$93.32 | +0.09%

Activity

AstraZenecas Imfinzi granted approval for gastric cancers.

Tue Nov 25, 2025

$93.24 | +1.88%

Activity

Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25 Key Companies | DelveInsight. Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25 Key Companies |. DelveInsightChronic heart failure (CHF) is a progressive condition where the heart is unable to pump blood effectively leading to significant morbidity and healthcare burden. The growing elderly population inherently at higher risk for CHF is a major driver

Tue Nov 25, 2025

$93.24 | +1.88%

Activity

FAQ About AZN Stock Insights

What is AZN current stock price?

What are AZN stock strengths?

What is AZN Risk Level?

What is AZN market cap and volume?

What is AZN current Stock IQ?

Should I buy AZN stock right now?

Is AZN a Strong Buy right now?

What does a 'Strong Buy' rating mean for AZN?

What does a 'Strong Sell' rating mean for AZN?

What factors influence AZN's Stock IQ?

Explore our AZN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored AZN Stock Strategies
Effective Risk Management

FIND US ON

Receive our AZN Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

AZN

Astrazeneca

Current Price

$91.11

+$0.94 | +1.04%

52W High

$94.02

MKT CAP

$285.62B

52W Low

$61.24

VOL

$1.66M

P/E Ratio

30.27

AVG VOL

$4.91M

RSI

61.32

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

AZN Rewards

Earnings are forecast to grow

AZN Rewards

Upgraded on attractively valued

AZN Rewards

Trading below its fair value

AZN Rewards

Outperform the market

Linked to AZN

Symbol

IQ

Close

Change

NVS

4.27

133.87

+1.17%

PFE

3.94

25.57

+1.65%

MRK

4.03

102.08

+1.05%

SNY

4.02

49.85

+0.02%

TEVA

4.23

27.29

+1.54%

AZN Price Performance

$81.35 (+12.00%)

$81.22 (+12.18%)

$71.85 (+26.81%)

$66.23 (+37.57%)

1year

6month

3month

1month

AZN Analysts Opinion

AZN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

AZN Analysts Opinion

AZN Analysts opinion is negative and it remained unchanged from the past 3 months

AZN Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

96%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

75%

AZN Street Sentiment

AZN Street Sentiment is extremely bullish and have positive views on the near-term outlook

AZN Risk Level

AZN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

AZN Performance Sentiment

Sentiments overview associated with AZN events and the stock performance.

96%

0%

Positive

Negative

22 out of 23
events present

0 out of 23
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$93.32

Resistance
Price

$73.53

Current Price Range

$93.32

Show methods +

AZN Stock IQ

Login to unlock Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

AZN Latest Analysis

AstraZeneca (AZN) Named One of BofAs Top 25 Stocks for 2026. AstraZeneca PLC (NASDAQ:AZN) ranks among the Best Low Volatility Investments in December 2025. BofA Securities maintained its Buy rating on AstraZeneca PLC (NASDAQ:AZN) and increased its price target to $108.50 from $91.70 on November 25. AstraZeneca PLC (NASDAQ:AZN) was listed on the companys Europe 1 list of top ideas and ranked as one of its [….]

Today

$91.11 | +1.04%

Rating

AstraZeneca Hypertension Drug Baxdrostat Wins FDA Priority Review . (RTTNews) - AstraZenecas (AZN) New Drug Application (NDA) for experimental hypertension drug baxdrostat has been granted Priority Review by the United States Food and Drug Administration.

Tue Dec 2, 2025

$90.17 | -0.39%

Activity

Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight. Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies |. DelveInsightThe dynamics of the geographic atrophy market are expected to change in the coming years due to the rising global prevalence driven by aging populations demand for disease-mod

Mon Dec 1, 2025

$90.52 | -2.38%

Activity

Peter Lynch Detailed Fundamental Analysis - AZN. Below is Valideas guru fundamental report for ASTRAZENECA PLC (ADR) (AZN). Of the 22 guru strategies we follow AZN rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price rel

Mon Dec 1, 2025

$90.52 | -2.38%

Potential

United States Pushes United Kingdom to Spend More on Medicines in Deal to Avoid Tariffs. A lab run by the drugmaker AstraZeneca. President Trump has complained that wealthy European countries pay too little for medicines.

Mon Dec 1, 2025

$90.52 | -2.38%

Activity

Heres Why Astrazeneca (AZN) is a Strong Growth Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Fri Nov 28, 2025

$92.73 | -0.63%

Potential

AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers. The United States Food and Drug Administration (FDA) on Tuesday approved ) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil leucovorin oxaliplatin and docetaxel) for resectable early-stage and locally advanced gastric and .AZN is in positive territory. The approved regimen includes neoadjuvant(therapy before surgery) Imfinzi in combination with chemotherapy before

Wed Nov 26, 2025

$93.32 | +0.09%

Activity

AstraZeneca Announces Approval Of Imfinzi In The US . (RTTNews) - AstraZeneca (AZN AZN.L) said its Imfinzi or durvalumab in combination with standard-of-care FLOT chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage and locally advanced gastric and gastroesophageal junction can

Wed Nov 26, 2025

$93.32 | +0.09%

Activity

AstraZenecas Imfinzi granted approval for gastric cancers.

Tue Nov 25, 2025

$93.24 | +1.88%

Activity

Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25 Key Companies | DelveInsight. Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25 Key Companies |. DelveInsightChronic heart failure (CHF) is a progressive condition where the heart is unable to pump blood effectively leading to significant morbidity and healthcare burden. The growing elderly population inherently at higher risk for CHF is a major driver

Tue Nov 25, 2025

$93.24 | +1.88%

Activity

Discover AZN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of AZN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our AZN Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

AZN Stock trends

AZN Stock performance

AZN Stock analysis

AZN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AZN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AZN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

AZN Stock Analysis & IQ Rating | Astrazeneca

AZN Stock IQ

AZN Target Price

AZN Risk Level

AZN Analysts Opinion

AZN Street Sentiment

AZN Performance Sentiment

Technical Price Levels

Explore our AZN Stock insights

Receive our AZN Daily Alerts

AZN Street Sentiment

AZN Risk Level

Technical Price Levels

Discover AZN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of AZN. We're here to help you make informed investment decisions today.

Receive our AZN Daily Alerts

AZN Runner Alarm